June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effects of CD25siRNA Gene Transfer on High-Risk Rat Corneal Graft Rejection
Author Affiliations & Notes
  • zhao min
    The first affiliated hospital of chongqing medical university, Chongiqing, China
  • shi yunjie
    The first affiliated hospital of chongqing medical university, Chongiqing, China
  • Qin qin
    The first affiliated hospital of chongqing medical university, Chongiqing, China
  • Footnotes
    Commercial Relationships zhao min, None; shi yunjie, None; Qin qin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1950. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      zhao min, shi yunjie, Qin qin; Effects of CD25siRNA Gene Transfer on High-Risk Rat Corneal Graft Rejection. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1950.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Corneal graft rejection is the major cause of corneal failures. Previous studies have shown that the CD25 monoclonal antibody can inhibit corneal graft rejection during the acute phase of rejection in rat models. In the current study, we evaluated the safety and efficacy of the topical Entranster™ vector in rat corneal applications and further investigated the effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection.

Methods: Fluorescence detection, clinical assessment, HE,TUNEL and CD11b assays were used to evaluate the safety and efficacy of CD25siRNA gene transfer in normal SD rat corneas.Recipient right corneas were alkali burned to mimic high-risk models before transplantation.Donor cornea (Wistar rat) was grafted into orthotopic recipient right graft bed(SD rat) on day 14 after alkali burn.Four groups were randomly divided:control group, Entranster™`- control CD25siRNA instilled treatment, Entranster™`-CD25siRNA instilled treatment,and Entranster™`-CD25siRNA twice instilled treatment.Rejection reaction was observed with a slit lamp microscope.The mean survival time and rejection index(RI) were calculated.,western blotting,qRT-PCR, immunohistochemistry,HE and TEM were detected in all grafts.

Results: Low toxicity, no immunogenicity and high transfection efficiency were observed in rat corneas treated with the Entranster™ vector. Reduced endothelial cell apoptosis, inflammatory cell infiltration and graft neovascularisation were observed in the CD25siRNA treatment groups. The graft survival curves showed that CD25siRNA treatment significantly prolonged graft survival time, with better graft transparency and less graft oedema.Lower CD25 and higher IL-10 expression were detected in the CD25siRNA treatment groups during the study period, and a higher FOXP3 level was found in the CD25siRNA group than the CD25siRNA-twice group on days 14 and 21 post-operation.

Conclusions: The Entranster™ vector is an effective vector for corneal gene therapy. CD25 siRNA gene transfer inhibits corneal graft rejection via upregulation of anti-inflammatory molecule expression.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×